Special Issue "Prostate Cancer Progression"
Deadline for manuscript submissions: closed (25 October 2023) | Viewed by 6286
Interests: metastatic prostate cancer; hormonal therapy; chemotherapy; immunotherapy; PARP inhibition; combination therapies; emerging (pre)clinical mCRPC treatment options; biomarkers
Special Issues, Collections and Topics in MDPI journals
Prostate cancer (PC) is one of the most prevalent malignancies of the present day. While most cases are diagnosed at a localized stage, a considerable number of patients with intermediate or high-risk localized, locally advanced or metastatic cancer die from the disease itself each year. Although therapeutic advances have been introduced in the field of metastatic PC in recent years, androgen deprivation therapy (ADT) remains the leading therapeutic backbone for metastatic PC. However, most patients develop castration resistance. The exact mechanisms driving the progression from androgen-dependent PC to castration-resistant prostate cancer (CRPC) are not completely understood.In recent years, the treatment landscape of metastatic CRPC (mCRPC) has substantially improved due to the availability of different agents. However, fast tumor progression, cross-resistance, the use of these substances in earlier (hormone-sensitive) stages of the disease, and patient-related factors should be taken into account when assessing which is the optimal treatment sequencing in the setting of mCRPC. This Special Issue aims, on one hand, to better understand the biological mechanisms of tumor progression and, on the other hand, to elucidate recent clinical developments in the treatment of both localized and metastatic disease.
Dr. Isabel Heidegger-Pircher
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- prostate cancer
- localized disease
- metastatic prostate cancer
- novel therapies
- combination therapies
- clinical research
- translational research
- basic research